𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study

✍ Scribed by Thatcher, N; Dazzi, H; Johnson, RJ; Russell, S; Ghosh, AK; Moore, M; Chadwick, G; Craig, RDP

Book ID
109836273
Publisher
Nature Publishing Group
Year
1989
Tongue
English
Weight
980 KB
Volume
60
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
✍ G. R. C. McLeod; D. B. Thomson; P. Hersey πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r